Pipeline

ADC Program

Target

Indication

Platform

Discovery

Preclinical

P1 Dose
Escalation

P1 Dose
Expansion

P2 Pivotal Study

P3

Phase

Mersana’s innovative platforms are a highly efficient engine that enable us to build a robust discovery pipeline for us and our partners. Our ADCs in preclinical studies and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need. We believe our platforms create an opportunity for ADCs with improved safety and efficacy relative to those developed using first-generation technology. Our lead asset, upifitamab rilsodotin (UpRi), is a first-in-class Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies;  and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also developing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines.

ADC ProgramTargetIndicationPlatformDiscoveryPreclinicalP1P1P2P3
Clinical
Upifitamab
Rilsodotin (UpRi)*
NaPi2b
Platinum-Resistant Ovarian Cancer Dolaflexin
XMT-1536*
NaPi2b
Platinum-Sensitive Ovarian Cancer Dolaflexin
XMT-1536*
NaPi2b
Recurrent Platinum-Sensitive Ovarian Cancer Maintenance Dolaflexin
Discovery
XMT-1660
B7-H4
Multiple Solid Tumors Dolasynthen
XMT-2056**
Novel HER2 Epitope
Multiple Solid Tumors Immunosynthen
XMT-2068
Undisclosed
Undisclosed Immunosynthen
XMT-2175
Undisclosed
Undisclosed Immunosynthen
Multiple Programs
Undisclosed
Undisclosed Immunosynthen Dolasynthen Dolaflexin
Collaborators
Multiple
Undisclosed Dolasynthen
Multiple
Undisclosed Dolaflexin
5T4
Undisclosed Dolaflexin
ADC Program Target Indication Platform Phase
upifitamab
rilsodotin (UpRi)*
NaPi2b Platinum-Resistant Ovarian Cancer Dolaflexin P2 Pivotal Study
upifitamab
rilsodotin (UpRi)*
NaPi2b Platinum-Resistant Ovarian Cancer Dolaflexin P1 Dose Escalation
upifitamab
rilsodotin (UpRi)*
NaPi2b Recurrent Platinum-Sensitive Ovarian Cancer Maintenance Dolaflexin P3
XMT-1592* NaPi2b Ovarian Cancer NSCLC Adenocarcinoma Dolasynthen P1 Dose Escalation
XMT-1660 B7-H4 Multiple Solid Tumors Dolasynthen P1 Dose Escalation
XMT-2056** HER2 Undisclosed Immunosynthen P1 Dose Escalation
XMT-2068 Undisclosed Undisclosed Immunosynthen Discovery
XMT-2175 Undisclosed Undisclosed Immunosynthen Discovery
Multiple Programs Undisclosed Undisclosed Immunosynthen Preclinical
Multiple Programs Undisclosed Undisclosed Immunosynthen Dolasynthen Dolaflexin Discovery
Multiple
Janssen Logo
Multiple Undisclosed Dolasynthen Discovery
Multiple
EMD Logo
Multiple*** Undisclosed Dolaflexin P1 Dose Escalation
ASN004
Asana Logo
5T4 Undisclosed Dolaflexin P1 Dose Escalation

*NaPi2b antibody used in UpRi (formerly XMT-1536) is in-licensed from Recepta Biopharma. Recepta has rights to commercialize UpRi in Brazil.
**XMT-2056 is wholly owned by Mersana, with GSK having an exclusive global license option to co-develop and commercialize the candidate
***EMD Serono is an affiliate of Merck KGaA